Zenith Technologies expands US presence
Mike Smith, US sales manager, Zenith Technologies.
Expansion is the result of the demand for the company's automation, process control and serialization technology services.
Zenith Technologies is expanding its US presence by opening two new offices on the West Coast of the US to meet greater demand for its automation, process control and serialization technology support services.
Marking 10 years since the company first opened a US base in Pennsylvania, the new sites in Oakland and San Diego will help the life science technology firm deliver a more localized service to its North American customers.
Zenith Technologies’ clients range from small and mid-sized pharma and biotech companies to contract manufacturing organisations and big pharma firms.
The decision to open the new offices comes following an increase in demand for its automation manufacturing software systems and the significant biotech sector expansions in Southern and Northern California.
Mike Smith, US sales manager at Zenith Technologies said: “We are looking forward to bolstering our US presence with the opening of these two new sites as it means we can provide complete coverage of service in the US from coast to coast.
“Expanding into such high growth areas for the life science and biotechnology industry means it is a really exciting time for our company and a great way to mark a decade of presence in North America.”
Both offices will act as a hub for critical project aid, back office assistance and managed services, allowing Zenith Technologies to provide improved service and on-the-ground support to its customer base.
The company’s US expansion initially began as a single project in Pennsylvania in 2006 but has grown into six offices across the US and close to 100 employees servicing a diverse client base.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.